HoldingsChannel.com
INmune Bio insider buying image
The table below summarizes the most recent INmune Bio insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why INmune Bio insider buys are important for investors to follow.
DateInsiderPriceAmount
4-19-2024
Insider Buy
Scott Juda
Director
$8.32
CAGR »
$246,296.96
29,603 shares
4-19-2024
Insider Buy
Mark William Lowdell
Chief Scientific Officer
$8.32
CAGR »
$119,999.36
14,423 shares
4-19-2024
Insider Buy
Raymond Joseph Tesi
President and CEO
$8.32
CAGR »
$149,992.96
18,028 shares
4-19-2024
Insider Buy
David J. Moss
CFO, Treasurer & Secretary
$8.32
CAGR »
$149,992.96
18,028 shares
5-27-2022
Insider Buy
David J. Moss
CFO, Treasurer & Secretary
$6.42
CAGR »
$68,649.00
10,700 shares
11-17-2021
Insider Buy
Scott Juda
Director
$13.55
CAGR »
$33,875.00
2,500 shares
8-21-2019
Insider Buy
Scott Juda
Director
$6.00
CAGR »
$30,000.00
5,000 shares
8-20-2019
Insider Buy
Raymond Joseph Tesi
President & CEO
$5.99
CAGR »
$11,987.19
2,000 shares
8-20-2019
Insider Buy
David J. Moss
CFO, Treasurer & Secretary
$5.65
CAGR »
$16,950.00
3,000 shares
8-9-2019
Insider Buy
Raymond Joseph Tesi
President & CEO
$7.03
CAGR »
$14,058.29
2,000 shares
6-3-2019
Insider Buy
Scott Juda
$6.00
CAGR »
$60,000.00
10,000 shares
5-6-2019
Insider Buy
David J. Moss
CFO, Treasurer & Secretary
$10.71
CAGR »
$53,550.00
5,000 shares
5-2-2019
Insider Buy
Raymond Joseph Tesi
President & CEO
$10.75
CAGR »
$119,325.00
11,100 shares
5-8-2019
Insider Buy
Linda F. Powers
$9.00
CAGR »
$555,003.00
61,667 shares

Also See: Institutional Holders of INMB
Also See: SEC filings

INMB Performance Since Insider Purchase
Below we present the annualized performance delivered by INmune Bio stock since 4-19-2024 (the date of the most recent insider purchase). The performance of the investment from the time INmune Bio insider buying occurred is the ultimate test of whether insiders were right about INMB being a good buy.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/22/2024
End date: 04/23/2024
Start price/share: $10.62
End price/share: $10.14
Dividends collected/share: $0.00
Total return: -4.56%
Annualized Gain: -1,666.12%
Starting investment: $10,000.00
Ending investment: $9,544.00
Years: 0.00

INmune Bio Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent INmune Bio insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding INMB

Quotes delayed 20 minutes

Email EnvelopeFree INMB Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Other companies seeing insider buying close in time to when the INmune Bio Insider Buying occurred are:

MainStay CBRE Global Infrastructure Megatrends Term Fund Insider Buying
abrdn Life Sciences Investors Insider Buying
Alzamend Neuro Insider Buying
Abrdn Global Infrastructure Income Fund Insider Buying
Texas Pacific Land Insider Buying
MainStreet Bancshares Insider Buying
RENN Fund Insider Buying
Community Trust Bancorp Insider Buying
WestAmerica Bancorporation Insider Buying
RXO Insider Buying

INmune Bio Insider Buying | www.HoldingsChannel.com

Copyright © 2013 - 2024, All Rights Reserved Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.